Antinociceptive Properties of Intravesical/needle-free Administration of AbobotulinumtoxinA in a Rodent Model of Chronic Visceral Pain: in Vivo and Histological Evidence

Overview

Journal J Neural Transm (Vienna)

Specialties Neurology
Physiology

Date 2025 Mar 16

PMID 40089646

Authors

Celine Auge

Mathieu Vogt

Vincent Martin

Stephane Lezmi

Xavier Game

Philippe Lluel

Jacquie Maignel

Affiliations

Soon will be listed here.

Abstract

While interstitial cystitis along with bladder pain syndrome (IC/BPS) is still poorly treated, published clinical evidence suggests that onabotulinumtoxinA (natural botulinum neurotoxin type A (BoNT/A)) intradetrusor injections is efficient in IC/BPS. However, as bladder instillation could be a safer and more convenient administration route, we aimed to investigate the effect of BoNT/A needle-free administration in an IC/BPS rodent model. Cyclophosphamide (CYP) was used to induce IC/BPS in rats. The resulting symptoms mimicked the main key features of human non-ulcerative IC/BPS. AbobotulinumtoxinA (aboBoNT-A) or reference compounds used in the clinic were delivered as a single intravesical administration into the bladder via the urethra. Visceral allodynia and hyperalgesia were assessed at the abdominal level with von Frey filaments before and after bladder pain induction. The levels of BoNT/A-cleaved SNAP25 (c-SNAP25), total SNAP25 (SNAP25), beta-3 tubulin and CGRP in bladders were also quantified using immunohistochemistry (IHC), as well as the histopathological lesions. AboBoNT-A was well tolerated up to 30 U/rat. Allodynia and hyperalgesia were significantly decreased after aboBoNT-A dosing, with higher efficacy compared to references. c-SNAP25 IHC levels were low and similar in the detrusor for the 3 aboBoNT-A groups. Neither CYP or aboBoNT-A induced any change in the amount of SNAP25, beta-3 tubulin or CGRP. Some CYP-induced histopathological lesions showed a trend in improvement under aboBoNT-A. AboBoNT-A displayed analgesic properties that could translate into better therapies for visceral pain. Interestingly, intravesical (needle-free) administration seems like a promising and reproducible route for botulinum toxin therapy in patients with IC/BPS.

References

Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford A, Davis J . Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005; 174(3):977-82. DOI: 10.1097/01.ju.0000169481.42259.54. View

Asfaha S, Cenac N, Houle S, Altier C, Papez M, Nguyen C . Protease-activated receptor-4: a novel mechanism of inflammatory pain modulation. Br J Pharmacol. 2006; 150(2):176-85. PMC: 2042908. DOI: 10.1038/sj.bjp.0706975. View

Ashraf S, Clarkson T, Malykhina A . Therapeutic Approaches for Urologic Chronic Pelvic Pain Syndrome; Management: Research Advances, Experimental Targets, and Future Directions. J Pharmacol Exp Ther. 2024; 390(2):222-232. PMC: 11264256. DOI: 10.1124/jpet.123.002081. View

Auge C, Game X, Vergnolle N, Lluel P, Chabot S . Characterization and Validation of a Chronic Model of Cyclophosphamide-Induced Interstitial Cystitis/Bladder Pain Syndrome in Rats. Front Pharmacol. 2020; 11:1305. PMC: 7485435. DOI: 10.3389/fphar.2020.01305. View

Auge C, Basso L, Blanpied C, Vergnolle N, Game X, Chabot S . Pain Management in a Model of Interstitial Cystitis/Bladder Pain Syndrome by a Vaccinal Strategy. Front Pain Res (Lausanne). 2022; 2:642706. PMC: 8915701. DOI: 10.3389/fpain.2021.642706. View

Berry S, Elliott M, Suttorp M, Bogart L, Stoto M, Eggers P . Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011; 186(2):540-4. PMC: 3513327. DOI: 10.1016/j.juro.2011.03.132. View

Chiu B, Tai H, Chung S, Birder L . Botulinum Toxin A for Bladder Pain Syndrome/Interstitial Cystitis. Toxins (Basel). 2016; 8(7). PMC: 4963834. DOI: 10.3390/toxins8070201. View

Chuang Y, Yoshimura N, Huang C, Chiang P, Chancellor M . Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol. 2004; 172(4 Pt 1):1529-32. DOI: 10.1097/01.ju.0000137844.77524.97. View

Chuang Y, Tyagi P, Huang C, Yoshimura N, Wu M, Kaufman J . Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol. 2009; 182(2):786-92. DOI: 10.1016/j.juro.2009.03.083. View

10.

Chuang Y, Huang T, Tyagi P, Huang C . Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using Low Energy Shock Waves. J Urol. 2016; 196(2):599-608. DOI: 10.1016/j.juro.2015.12.078. View

11.

Comperat E, Reitz A, Delcourt A, Capron F, Denys P, Chartier-Kastler E . Histologic features in the urinary bladder wall affected from neurogenic overactivity--a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol. 2006; 50(5):1058-64. DOI: 10.1016/j.eururo.2006.01.025. View

12.

Dorner M, Schulz K, Kull S, Dorner B . Complexity of botulinum neurotoxins: challenges for detection technology. Curr Top Microbiol Immunol. 2012; 364:219-55. DOI: 10.1007/978-3-642-33570-9_11. View

13.

Frevert J, Dressler D . Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?. Biologics. 2011; 4:325-32. PMC: 3010823. DOI: 10.2147/BTT.S14902. View

14.

Gabella G . Afferent nerve fibres in the wall of the rat urinary bladder. Cell Tissue Res. 2018; 376(1):25-35. DOI: 10.1007/s00441-018-2965-0. View

15.

Gafni-Kane A, Botros S, Du H, Sand R, Sand P . Measuring the success of combined intravesical dimethyl sulfoxide and triamcinolone for treatment of bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2012; 24(2):303-11. DOI: 10.1007/s00192-012-1832-x. View

16.

Homma Y, Akiyama Y, Tomoe H, Furuta A, Ueda T, Maeda D . Clinical guidelines for interstitial cystitis/bladder pain syndrome. Int J Urol. 2020; 27(7):578-589. DOI: 10.1111/iju.14234. View

17.

Hu J, Tzeng H, Lee W, Li J, Chuang Y . Promising Experimental Treatment in Animal Models and Human Studies of Interstitial Cystitis/Bladder Pain Syndrome. Int J Mol Sci. 2024; 25(15). PMC: 11312208. DOI: 10.3390/ijms25158015. View

18.

Ibrahim H, Retailleau K, Hornby F, Maignel J, Beard M, Daly D . A Novel Catalytically Inactive Construct of Botulinum Neurotoxin A (BoNT/A) Directly Inhibits Visceral Sensory Signalling. Toxins (Basel). 2024; 16(1). PMC: 10820156. DOI: 10.3390/toxins16010030. View

19.

Jhang J, Ho H, Jiang Y, Lee C, Hsu Y, Kuo H . Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition. PLoS One. 2018; 13(6):e0198816. PMC: 5991750. DOI: 10.1371/journal.pone.0198816. View

20.

Jiang Y, Jhang J, Lee Y, Kuo H . Low-Energy Shock Wave Plus Intravesical Instillation of Botulinum Toxin A for Interstitial Cystitis/Bladder Pain Syndrome: Pathophysiology and Preliminary Result of a Novel Minimally Invasive Treatment. Biomedicines. 2022; 10(2). PMC: 8962423. DOI: 10.3390/biomedicines10020396. View